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CASE REPORT
Reversible cycloplegia caused by duloxetine: a case report
Rabia Nazik Yüksela, Vahap Ozan Kotanb and Erol Göka a
aDepartment of Psychiatry, Health Sciences University Ankara Numune Research & Training Hospital, Ankara, Turkey; bDepartment of
Psychiatry, Baskent University Hospital, Ankara, Turkey
ABSTRACT
A Duloxetine is a balanced and potent dual reuptake inhibitor of serotonin and norepinephrine
(SNRI) that has previously been shown to be effective in the treatment of major depressive
disorder (MDD), generalized anxiety disorder, and diabetic peripheral neuropathic pain
(DPNP). Cycloplegia is paralysis of the ciliary muscle of the eye, resulting in a loss of
accommodation. Here, we present a reversible cycloplegia case caused by duloxetine use.
The patient was a 24 years-old woman with MDD diagnosis. Patient had somatic symptoms
like fatigue, myalgia, and headache, besides her depressive symptoms for the last two
months. Escitalopram and sertraline were used for her MDD before and she had to quit both
owing to side effects such as nausea and drowsiness. Duloxetine 30mg/day treatment was
started in our outpatient clinic. In her first follow-up exam, she reported light sensitivity and
increased visual impairment. The visual impairment led dizziness and an increase in
headache. She was consulted to ophthalmology unit of our hospital and cycloplegia was
detected in her eye examination. Duloxetine was stopped in the ninth day of treatment but
cycloplegia negatively affected the patient’s daily life for almost 4 weeks and impaired her
functionality. Because of the paralysis of the ciliary muscle, the curvature of the lens can no
longer be adjusted to focus on nearby objects. Eye pain, changes in vision and swelling or
redness in or around the eye are mentioned as possible visual side effects in the medication
of duloxetine. The ocular and visual side effects from a patient’s systemic medication can
range from mild to severe. These side effects may or may not be serious enough to warrant
discontinuing treatment. Cycloplegia seems as a rare adverse effect in antidepressant
treatment and may take a long time to wash out. Recognition of ocular and visual
side effects is important to prevent and minimize serious complications. In such visual
disturbances, eye examination of the patient should be performed and the responsible drug
should be discontinued as early as possible.
ARTICLE HISTORY
Received 8 March 2017
Accepted 16 May 2017
KEYWORDS
Duloxetine; cycloplegia; side
effects; adverse effects
Introduction
Duloxetine is a balanced and potent dual reuptake
inhibitor of serotonin and norepinephrine that has pre-
viously been shown to be effective in the treatment of
major depressive disorder (MDD), generalized anxiety
disorder and diabetic peripheral neuropathic pain [1].
Absorption of duloxetine begins two hours after oral
administration, reaching a maximum plasma concen-
tration in six hours. Half-life and volume of distri-
bution are 12 hours and 1640 L, respectively. Similar
remission rates with selective serotonin-reuptake
inhibitors (SSRIs) increase the use of SNRIs in MDD
[2]. The adverse effects of duloxetine are similar to tra-
ditional SSRIs. Most common adverse effect of dulox-
etine is nausea that is generally associated with
discontinuation. Other common adverse effects are
constipation, insomnia, hypersomnia, dizziness, weak-
ness, drowsiness, sedation, fatigue, diarrhea, headache
and xerostomia [3]. With the increased use of duloxe-
tine, clinicians have begun to encounter different
adverse effects. Cycloplegia is paralysis of the ciliary
muscle of the eye, resulting in a loss of accommodation
[4]. In this case report, we present a reversible cyclople-
gia caused by duloxetine use.
Case
Miss A, is a 24-year-old single patient, who lost her
mother four years ago and lives with her retired father.
She has had somatic symptoms like fatigue, myalgia
and headache, besides her depressive symptoms like
anhedonia, feeling of unworthiness, pessimistic
thoughts, irritability, reduced self-confidence, aversion,
lack of appetite and insomnia for last two months. Her
social life has frustrated. She was examined in internal
medicine clinic in last month for fatigue and her blood
tests and revealed no problems.
In mental state examination, her affect was
depressed and her range of mood was reduced. She
appeared anxious and irritable. She answered questions
at slow rate and speed. In her thought content, she did
not have any suicidal thoughts or psychotic symptoms.
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She has been diagnosed with MDD. She mentioned
that she used escitalopram and sertraline for MDD
four years ago while she was at college education. She
stated that she had to quit escitalopram and sertraline
owing to side effects such as nausea and drowsiness.
Duloxetine 30 mg/day treatment was begun in our out-
patient clinic. In her first routine control at the end of
first week, she suffered from light sensitivity and an
increasing visual impairment. The visual impairment
led dizziness and an increase in headache. She was con-
sulted to ophthalmology unit of our hospital. She had
no history of ocular disease or use of any eye drops.
In the eye examination, her pupils were mydriatic,
equal, round and were not reactive to light. Extraoculer
movements were in full range. In slit lamp examin-
ation, the anterior compartment of the eye was normal
and clear. Detailed ocular examination revealed normal
fundus and intraocular pressure. Cycloplegia was
detected in her eye examination.
A magnetic resonance imaging (MRI) of the brain
with contrast and neurological examination was nor-
mal. A contrasted MRI report of the brain and neuro-
logical examination was also normal. Cycloplegia was
assessed with Naranjo’s adverse drug reaction (ADR)
probability scale and the score was 9. According to
this scale, it is considered that; 9 points and above: defi-
nite, 5–8 points: probable 1–4 points: possible and 0
points: doubtful ADRs [5]. Cycloplegia was considered
to be associated with duloxetine. Duloxetine was
stopped in the 9th day of treatment but cycloplegia per-
sisted for almost 4 weeks and negatively affected the
patient’s daily life and impaired her functionality.
Dıscussion
Cycloplegia is paralysis of the ciliary muscle of the eye,
resulting in a loss of accommodation. Because of the
paralysis of the ciliary muscle, the curvature of the
lens can no longer be adjusted to focus on nearby
objects.
The factors that are likely to lead to cycloplegia in
this case should be considered as adverse effect of
duloxetine on ciliary muscle, neurological factors as
Adie’s tonic pupil, intracranial lesions affecting the
third (oculomotor) nerve and third nerve nucleus.
In our case, the patient had no history of any eye dis-
eases or neurological disorders and before the duloxe-
tine administration, she had no complaints about her
vision. Normal MRI report, normal neurological exam-
ination and the gradual recovery after the cessation of
duloxetine, supported the idea that cycloplegia was an
adverse reaction induced by duloxetine.
Antidepressants have various ocular and visual
adverse effects. For instance, the tricyclic antidepressants
produce many anticholinergic side effects. Symptoms of
blurred vision, cycloplegia and dry eye are transient
and reversible [6]. Reducing or changing the medication
may improve the symptoms. In some cases, near vision
lenses may be helpful. SSRIs are known not to have any
significant ocular effects. Eye pain, changes in vision
and swelling or redness in or around the eye are men-
tioned as possible visual side effects in the medication
of duloxetine. The ocular and visual side effects from a
patient’s systemic medication can range from mild to
severe. These side effects may or may not be serious
enough to warrant discontinuing treatment. Recognition
of ocular and visual side effects is important to prevent
and minimize serious complications.
Conclusion
Cycloplegia seems as a rare but disturbing adverse
effect in antidepressant treatment and may take a
long time to wash out. In case of visual disturb-
ances, eye examination of the patient should
be performed and the responsible drug should
be discontinued as soon as the cycloplegia was
found.
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